DaVita Inc. (DVA): Price and Financial Metrics

DaVita Inc. (DVA): $127.60

2.64 (+2.11%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add DVA to Watchlist
Sign Up

Industry: Medical - Services

Industry

C

Ranked

#6 of 67

in industry

DVA Price/Volume Stats

Current price $127.60 52-week high $128.28
Prev. close $124.96 52-week low $71.51
Day low $124.42 Volume 854,300
Day high $128.04 Avg. volume 883,338
50-day MA $110.32 Dividend yield N/A
200-day MA $100.10 Market Cap 11.19B

DVA Stock Price Chart Interactive Chart >

DVA POWR Grades

  • Growth is the dimension where DVA ranks best; there it ranks ahead of 96.14% of US stocks.
  • The strongest trend for DVA is in Stability, which has been heading down over the past 26 weeks.
  • DVA ranks lowest in Momentum; there it ranks in the 26th percentile.

DVA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for DVA is 9.93 -- better than 96.2% of US stocks.
  • The ratio of debt to operating expenses for DAVITA INC is higher than it is for about 82.5% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 17.99 for DAVITA INC; that's greater than it is for 97.37% of US stocks.
  • If you're looking for stocks that are quantitatively similar to DAVITA INC, a group of peers worth examining would be APA, CFBK, QRTEA, BKU, and LARK.
  • DVA's SEC filings can be seen here. And to visit DAVITA INC's official web site, go to www.davita.com.

DVA Valuation Summary

  • In comparison to the median Healthcare stock, DVA's price/sales ratio is 80.95% lower, now standing at 0.8.
  • DVA's price/earnings ratio has moved up 1.1 over the prior 243 months.

Below are key valuation metrics over time for DVA.

Stock Date P/S P/B P/E EV/EBIT
DVA 2023-12-29 0.8 8.0 15.7 16.7
DVA 2023-12-28 0.8 8.0 15.7 16.7
DVA 2023-12-27 0.8 7.9 15.6 16.6
DVA 2023-12-26 0.8 8.0 15.7 16.7
DVA 2023-12-22 0.8 7.9 15.6 16.6
DVA 2023-12-21 0.8 8.0 15.7 16.7

DVA Growth Metrics

    The year over year net cashflow from operations growth rate now stands at 18.38%.
  • The 5 year cash and equivalents growth rate now stands at 1.1%.
  • The 3 year revenue growth rate now stands at 2.81%.
Over the past 15 months, DVA's revenue has gone up $71,074,000.

The table below shows DVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 11,636.97 1,750.736 679.77
2022-06-30 11,626.6 1,607.156 834.158
2022-03-31 11,616.35 2,098.767 903.169
2021-12-31 11,618.8 1,930.876 978.45
2021-09-30 11,580.15 1,885.786 964.75
2021-06-30 11,565.9 1,801.561 863.67

DVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DVA has a Quality Grade of B, ranking ahead of 81.19% of graded US stocks.
  • DVA's asset turnover comes in at 0.661 -- ranking 45th of 81 Healthcare stocks.
  • LHCG, NTRA, and CHE are the stocks whose asset turnover ratios are most correlated with DVA.

The table below shows DVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.661 0.312 0.082
2021-06-30 0.666 0.314 0.078
2021-03-31 0.650 0.310 0.074
2020-12-31 0.651 0.308 0.077
2020-09-30 0.648 0.313 0.083
2020-06-30 0.643 0.310 0.082

DVA Price Target

For more insight on analysts targets of DVA, see our DVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $143.11 Average Broker Recommendation 2 (Hold)

DaVita Inc. (DVA) Company Bio


DaVita Inc. provides kidney dialysis services through a network of 2,816 outpatient dialysis centers in the United States, serving 204,200 patients, and 321 outpatient dialysis centers in 10 other countries serving 3,200 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives unless they receive a donor kidney. The company has a 37% market share in the U.S. dialysis market. It is organized in Delaware and based in Denver. (Source:Wikipedia)


DVA Latest News Stream


Event/Time News Detail
Loading, please wait...

DVA Latest Social Stream


Loading social stream, please wait...

View Full DVA Social Stream

Latest DVA News From Around the Web

Below are the latest news stories about DAVITA INC that investors may wish to consider to help them evaluate DVA as an investment opportunity.

Brookdale (BKD) Concludes Transactions to Extend Debt Repayment

Brookdale (BKD) completes two financing transactions to push its debt maturities until September 2025, thereby relieving it from the debt repayment burden for next year and focusing on core operations.

Yahoo | December 28, 2023

3 Reasons to Hold Zimmer Biomet (ZBH) Stock in Your Portfolio

Zimmer Biomet's (ZBH) focus on emerging markets raises optimism about the stock.

Yahoo | December 28, 2023

Three Reasons to Add Ecolab (ECL) Stock to Your Portfolio

Ecolab's (ECL) focus on R&D raises optimism about the stock.

Yahoo | December 28, 2023

The Zacks Analyst Blog Highlights DaVita, GE HealthCare Technologies and Hologic

DaVita, GE HealthCare Technologies and Hologic are part of the Zacks top Analyst Blog.

Yahoo | December 28, 2023

DVA vs. CHE: Which Stock Is the Better Value Option?

DVA vs. CHE: Which Stock Is the Better Value Option?

Yahoo | December 27, 2023

Read More 'DVA' Stories Here

DVA Price Returns

1-mo 19.06%
3-mo 28.10%
6-mo 24.59%
1-year 54.03%
3-year 24.94%
5-year 124.25%
YTD 21.80%
2023 40.30%
2022 -34.36%
2021 -3.10%
2020 56.47%
2019 45.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!